Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Amyloid in bone marrow smears of patients affected by multiple myeloma.
Petruzziello F, Zeppa P, Catalano L, Cozzolino I, Gargiulo G, Musto P, D'Auria F, Liso V, Rizzi R, Caruso N, Califano C, Piro E, Musso M, Bonanno V, Pia Falcone A, Tafuto S, Di Raimondo F, De Laurentiis M, Pane F, Palombini L, Rotoli B. Petruzziello F, et al. Among authors: tafuto s. Ann Hematol. 2010 May;89(5):469-74. doi: 10.1007/s00277-009-0857-9. Epub 2009 Nov 6. Ann Hematol. 2010. PMID: 19894050
A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice.
Pirozzi Palmese V, D'Ambrosio L, Di Gennaro F, Maisto C, de Marino R, Morisco A, Coluccia S, Di Gennaro P, De Lauro F, Raddi M, Gaballo P, Tafuto S, Celentano E, Lastoria S. Pirozzi Palmese V, et al. Among authors: tafuto s. Eur J Nucl Med Mol Imaging. 2023 May;50(6):1753-1764. doi: 10.1007/s00259-023-06112-8. Epub 2023 Jan 23. Eur J Nucl Med Mol Imaging. 2023. PMID: 36688980 Free PMC article.
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Singh S, et al. Among authors: tafuto s. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. Lancet. 2024. PMID: 38851203 Clinical Trial.
Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial.
Gridelli C, Gallo C, Morabito A, Iaffaioli RV, Favaretto A, Isa L, Barbera S, Gamucci T, Ceribelli A, Filipazzi V, Maione P, Rossi A, Barletta E, Signoriello S, De Maio E, Piccirillo MC, Di Maio M, Rocco G, Vecchione A, Perrone F; G-STEP Investigators. Gridelli C, et al. J Thorac Oncol. 2012 Jan;7(1):233-42. doi: 10.1097/JTO.0b013e318233d6c2. J Thorac Oncol. 2012. PMID: 22031232 Free article. Clinical Trial.
A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
Comella P, Gambardella A, Farris A, Maiorino L, Natale D, Massidda B, Casaretti R, Tafuto S, Lorusso V, Leo S; Southern Italy Cooperative Oncology Group. Comella P, et al. Among authors: tafuto s. Crit Rev Oncol Hematol. 2005 Feb;53(2):133-9. doi: 10.1016/j.critrevonc.2004.10.008. Crit Rev Oncol Hematol. 2005. PMID: 15661564 Clinical Trial.
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective Study.
Brighi N, La Rosa S, Rossi G, Grillo F, Pusceddu S, Rinzivillo M, Spada F, Tafuto S, Massironi S, Faggiano A, Antonuzzo L, Santini D, Sessa F, Maragliano R, Gelsomino F, Albertelli M, Vernieri C, Panzuto F, Fazio N, De Divitiis C, Lamberti G, Colao A, Fave GD, Campana D. Brighi N, et al. Among authors: tafuto s. Ann Surg. 2020 Mar;271(3):527-533. doi: 10.1097/SLA.0000000000002939. Ann Surg. 2020. PMID: 29995678
Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy.
Ottaiano A, Nappi A, Tafuto S, Nasti G, De Divitiis C, Romano C, Cassata A, Casaretti R, Silvestro L, Avallone A, Capuozzo M, Capozzi M, Maiolino P, Quagliariello V, Scala S, Iaffaioli VR. Ottaiano A, et al. Among authors: tafuto s. Oncology. 2016;90(1):36-42. doi: 10.1159/000442527. Epub 2016 Jan 6. Oncology. 2016. PMID: 26731722
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial.
Comella P, Massidda B, Filippelli G, Palmeri S, Natale D, Farris A, De Vita F, Buzzi F, Tafuto S, Maiorino L, Mancarella S, Leo S, Lorusso V, De Lucia L, Roselli M. Comella P, et al. Among authors: tafuto s. Ann Oncol. 2005 Jun;16(6):878-86. doi: 10.1093/annonc/mdi185. Epub 2005 Apr 18. Ann Oncol. 2005. PMID: 15837702 Free article. Clinical Trial.
Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor.
Lamberti G, Faggiano A, Brighi N, Tafuto S, Ibrahim T, Brizzi MP, Pusceddu S, Albertelli M, Massironi S, Panzuto F, Badalamenti G, Riccardi F, Butturini G, Gelsomino F, De Divitiis C, Modica R, Bongiovanni A, La Salvia A, Torchio M, Colao A, Ferone D, Campana D. Lamberti G, et al. Among authors: tafuto s. J Clin Endocrinol Metab. 2020 Jan 1;105(1):dgz035. doi: 10.1210/clinem/dgz035. J Clin Endocrinol Metab. 2020. PMID: 31545377
102 results